How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up

ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.

Zacks Investment Research • 16 hours ago

Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.

Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.

Barrons • May 15, 2026

My Top 10 Dividend Stocks For May

This dividend growth portfolio optimizes for payout ratios, EBITDA yield, and dividend growth, focusing on Dow Dividend 100 constituents. EOG Resources, Comcast, and Accenture receive the highest portfolio weights based on a multi-factor scoring system. The weighted portfolio offers a 3.28% forward dividend yield and a 12.4% five-year dividend CAGR.

Seeking Alpha • May 14, 2026

Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?

ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low.

Zacks Investment Research • May 13, 2026

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research • May 12, 2026

Abbott: Three Supercycles, Mispriced At A 10-Year Low

Abbott Laboratories trades at a decade low of 17.7x forward earnings despite 13.2% Q1 2026 Medical Devices growth and a 54-year dividend streak. Three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—could drive $1.27–$1.73 incremental EPS by 2028–2029. Consensus underestimates ABT's commercial leverage, with distribution synergies and CMS reimbursement expansion offering asymmetric upside not priced into current models.

Seeking Alpha • May 11, 2026

Abbott Laboratories Is On Sale, Don't Overlook It

Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak.

Seeking Alpha • May 9, 2026

Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.

Zacks Investment Research • May 8, 2026

Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows

These stocks all yield more than 2%. These companies have also been increasing their payouts for decades.

The Motley Fool • May 6, 2026

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • May 5, 2026